Urgent

Vernal keratoconjunctivitis (VKC)

Ocular allergy · Ophthalmology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic, bilateral, severe, typically spring-recurring ocular-surface allergic inflammation, usually in boys <10 years in warm/dry climates. Can cause corneal shield ulcers and vision loss, so it is not a benign conjunctivitis. DRAFT for clinician review.

Red flags

  • Corneal shield ulcer
  • Photophobia with decreased vision
  • Severe eye pain
  • Corneal opacity or plaque
  • Patient using unsupervised topical steroids (IOP/glaucoma/cataract/infection risk)

Assessment

Differential diagnosis

  • Atopic keratoconjunctivitis (perennial, adults, lower tarsus/inferior fornix)
  • Seasonal/perennial allergic conjunctivitis
  • Giant papillary conjunctivitis
  • Infective conjunctivitis
  • Toxic conjunctivitis

Investigations

  • Clinical: ocular pruritus + giant 'cobblestone' papillae on the upper tarsal conjunctiva; Horner-Trantas dots in the limbal form
  • Fluorescein staining to detect corneal shield ulcer / superficial keratopathy
  • No routine labs; allergy testing only if immunotherapy considered (VKC unlikely if aeroallergen testing negative — reconsider other causes)

Management

  • Basic eye care: avoid eye rubbing; avoid nonspecific triggers (wind, heat, sun, salt water); cool compresses; artificial tears
  • Start topical dual-acting mast-cell stabiliser / H1 antihistamine
  • Add oral antihistamine for moderate–severe disease not responding in 2–3 weeks
  • Refractory disease → topical corticosteroid (ophthalmologist-supervised)
  • Steroid-sparing topical cyclosporine/tacrolimus for frequent/prolonged steroid need
  • Corneal shield ulcer → urgent ophthalmology
  • Refer to allergist for immunotherapy if uncontrolled

Drugs & doses

Topical dual-acting mast-cell stabiliser + H1 antihistamine (first-line) — e.g. olopatadine, ketotifen fumarate, alcaftadine, azelastine, epinastine, bepotastine; standard doses, daily throughout the season; onset within minutes.
Topical mast-cell stabiliser (alternative) — cromolyn sodium, nedocromil, or lodoxamide; dosed 3–4×/day; slow onset (5–14 days), so start ~1 month before the season and not useful for acute symptoms.
Oral 2nd/3rd-generation H1 antihistamine (add-on for moderate–severe) — fexofenadine, loratadine, desloratadine, cetirizine, or levocetirizine; maximise dose; onset ½–2 h.
Topical corticosteroid for refractory disease (OPHTHALMOLOGIST only) — short high-dose burst (3–4 drops/day × 3–5 days, may repeat) or a taper over 1–3 weeks (twice daily ×1 wk, daily ×1 wk, alternate-day ×1 wk). Prefer 'soft' steroids: loteprednol etabonate 0.5/0.38/0.2%, prednisolone acetate 0.12%, or fluorometholone (lower IOP risk). Reserve prednisolone acetate 1% / dexamethasone 0.1% for severe bursts. NOT if corneal epithelium compromised; avoid >6 weeks.
Topical cyclosporine (steroid-sparing) — 0.1% one drop each eye 4×/day; may increase to 2% one drop each eye twice daily in severe/unresponsive disease. Alternative: topical tacrolimus (more burning).
Corneal shield ulcer — topical cyclosporine (NOT corticosteroid, which impairs re-epithelialisation) plus broad-spectrum antibiotic cover, e.g. moxifloxacin or gatifloxacin 4×/day; debridement / bandage contact lens / temporary tarsorrhaphy may be needed.
Systemic cyclosporine 2.5–5 mg/kg/day during the season — rarely needed, specialist use for severe steroid-dependent disease. Omalizumab reported effective in refractory cases.

Disposition

Mild–moderate: discharge on dual-acting drops with ophthalmology follow-up. Corneal shield ulcer, vision threat, or need for topical steroid: same-day/urgent ophthalmology referral.

Complications & pitfalls

  • Corneal shield ulcer
  • Corneal scarring and neovascularisation
  • Amblyopia
  • Steroid-induced glaucoma and cataract
  • Secondary infective keratitis

Exam pearls

  • Nearly all patients itch and have giant upper-tarsal cobblestone papillae
  • Topical steroids are effective but MUST be ophthalmologist-monitored — risk of blindness if IOP unmonitored
  • In known patients, start prophylaxis ~1 month before the usual season
  • Usually outgrown by puberty

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.